These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 35016131)
61. The value of gadoxetic acid-enhanced MRI for differentiation between hepatic microabscesses and metastases in patients with periampullary cancer. Choi SY; Kim YK; Min JH; Cha DI; Jeong WK; Lee WJ Eur Radiol; 2017 Oct; 27(10):4383-4393. PubMed ID: 28342102 [TBL] [Abstract][Full Text] [Related]
63. Early start of chemotherapy after resection of primary colon cancer with synchronous multiple liver metastases: a case report. Yoshida Y; Hoshino S; Shiwaku H; Beppu R; Tanimura S; Tanaka S; Yamashita Y Case Rep Oncol; 2011 May; 4(2):250-4. PubMed ID: 21677890 [TBL] [Abstract][Full Text] [Related]
64. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. Tamandl D; Gruenberger B; Herberger B; Kaczirek K; Gruenberger T J Surg Oncol; 2009 Oct; 100(5):364-71. PubMed ID: 19235181 [TBL] [Abstract][Full Text] [Related]
65. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994 [TBL] [Abstract][Full Text] [Related]
66. Delayed tumour enhancement on gadoxetate-enhanced MRI is associated with overall survival in patients with colorectal liver metastases. Cheung HMC; Karanicolas PJ; Coburn N; Seth V; Law C; Milot L Eur Radiol; 2019 Feb; 29(2):1032-1038. PubMed ID: 29992388 [TBL] [Abstract][Full Text] [Related]
67. Erratum to 'Prostate cancer local staging using biparametric MRI: Assessment and comparison with multiparametric MRI' [Eur. J. Radiol. 132 (2020) 109350]. Christophe C; Montagne S; Bourrelier S; Roupret M; Barret E; Rozet F; Comperat E; Coté JF; Lucidarme O; Cussenot O; Granger B; Renard-Penna R Eur J Radiol; 2020 Dec; 133():109417. PubMed ID: 33229110 [No Abstract] [Full Text] [Related]
68. MR liver imaging with Gd-EOB-DTPA: a delay time of 10 minutes is sufficient for lesion characterisation. van Kessel CS; Veldhuis WB; van den Bosch MA; van Leeuwen MS Eur Radiol; 2012 Oct; 22(10):2153-60. PubMed ID: 22645040 [TBL] [Abstract][Full Text] [Related]
69. Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxetic acid disodium-enhanced magnetic resonance imaging. Murata S; Matsushima S; Sato Y; Yamaura H; Kato M; Hasegawa T; Muro K; Inaba Y Abdom Radiol (NY); 2018 Dec; 43(12):3301-3306. PubMed ID: 29666951 [TBL] [Abstract][Full Text] [Related]
70. Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium. Koh DM; Brown G; Meer Z; Norman AR; Husband JE AJR Am J Roentgenol; 2007 Feb; 188(2):W154-61. PubMed ID: 17242222 [TBL] [Abstract][Full Text] [Related]
71. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Tyagi P; Grothey A Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510 [TBL] [Abstract][Full Text] [Related]
73. A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Kim Y; Kim TW; Han SW; Ahn JB; Kim ST; Lee J; Park JO; Park YS; Lim HY; Kang WK Cancer Res Treat; 2019 Jul; 51(3):1128-1134. PubMed ID: 30477287 [TBL] [Abstract][Full Text] [Related]
74. [Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)]. Sato A; Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Koizumi W; Mizunuma N; Takiuchi H Gan To Kagaku Ryoho; 2011 Apr; 38(4):561-9. PubMed ID: 21498982 [TBL] [Abstract][Full Text] [Related]
75. Atypical Enhancement of Gd-BOPTA on the Hepatobiliary Phase in Hepatic Metastasis from Carcinoid Tumor - Case Report. Pozowski P; Misiak P; Szymańska K; Mazur R; Sierpowska M; Silicki J; Celmer M; Łasecki M; Pawluś A; Zaleska-Dorobisz U Am J Case Rep; 2020 Sep; 21():e924280. PubMed ID: 32883944 [TBL] [Abstract][Full Text] [Related]
76. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662 [TBL] [Abstract][Full Text] [Related]